Problems and solutions to filling the drying drug pipeline for psychiatric disorders: a report from the inaugural 2012 CINP Think Tank.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  International Journal of Neuropsychopharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1017/S1461145713001077PMID 24063634
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapy.

  2013cited by this paper
• Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology

  2013cited by this paper
• Treatment-resistant depression and risk of suicide.

  2013cited by this paper
• Polypharmacy for schizophrenia

  2013cited by this paper
• Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice.

  2013cited by this paper
• Update on typical and atypical antipsychotic drugs.

  2013cited by this paper
• Obstacles to the Development of a Neuroprotective Therapy for Parkinson's Disease

  2013cited by this paper
• Nanotechnology for CNS delivery of bio-therapeutic agents

  2013cited by this paper
• CNVs: harbingers of a rare variant revolution in psychiatric genetics.

  2012cited by this paper
• Nonuniform Cardiac Denervation Observed by 11C-meta-Hydroxyephedrine PET in 6-OHDA-Treated Monkeys

  2012cited by this paper
• Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?

  2012cited by this paper
• Ketamine for depression: where do we go from here?

  2012cited by this paper
• Celecoxib enhances the effect of reboxetine and fluoxetine on cortical noradrenaline and serotonin output in the rat.

  2012cited by this paper
• Current progress in the genetic research of schizophrenia: relevance for drug discovery?

  2012cited by this paper
• Editorial: neurochemistry of schizophrenia and psychosis: the contribution of neuroimaging.

  2012cited by this paper
• Drug treatment for melanoma: progress, but who pays?

  2012cited by this paper
• Implications of geographical variation on clinical outcomes of cardiovascular trials.

  2012cited by this paper
• Neurochemistry of schizophrenia: the contribution of neuroimaging postmortem pathology and neurochemistry in schizophrenia.

  2012cited by this paper
• Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease

  2012cited by this paper
• Anatomy of an Epidemic – Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness in America

  2012cited by this paper
• Microfluidic technologies for accelerating the clinical translation of nanoparticles.

  2012cited by this paper
• Cognitive performance of individuals with schizophrenia across seven decades: a study using the MATRICS consensus cognitive battery.

  2012cited by this paper
• Nasal drug delivery

  2012cited by this paper
• Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy

  2012cited by this paper
• Novartis to shut brain research facility

  2011cited by this paper
• Reseña de "Anatomy of an epidemic. Magic bullets, psychiatric drugs and the astonishing rise of mental illness in America" de ROBERT WHITAKER

  2011cited by this paper
• A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia

  2011cited by this paper
• Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs

  2011cited by this paper
• Dissecting the Syndrome of Schizophrenia: Progress toward Clinically Useful Biomarkers

  2011cited by this paper
• The α4β2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats

  2010cited by this paper
• Animal models of schizophrenia.

  2010cited by this paper
• Agomelatine, the first melatonergic antidepressant: discovery, characterization and development

  2010cited by this paper
• Pre‐clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence

  2010cited by this paper
• Cross-species assessments of motor and exploratory behavior related to bipolar disorder.

  2010cited by this paper
• Discovery and Characterization of Novel Allosteric Potentiators of M1 Muscarinic Receptors Reveals Multiple Modes of Activity

  2009cited by this paper
• Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk

  2009cited by this paper
• Pharmacogenomics: The Promise of Personalized Medicine for CNS Disorders

  2009cited by this paper
• Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today.

  2009cited by this paper
• Common polygenic variation contributes to risk of schizophrenia and bipolar disorder

  2009cited by this paper
• Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models

  2009cited by this paper
• The 5-Choice Continuous Performance Test: Evidence for a Translational Test of Vigilance for Mice

  2009cited by this paper
• Personalized medicine in psychiatry: ethical challenges and opportunities

  2009cited by this paper
• A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men.

  2009cited by this paper
• Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders

  2009cited by this paper
• Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia

  2009cited by this paper
• Altered M1 Muscarinic Acetylcholine Receptor (CHRM1)-Gαq/11 Coupling in a Schizophrenia Endophenotype

  2009cited by this paper
• Disruptive insights in psychiatry: transforming a clinical discipline.

  2009cited by this paper
• Pharmacogenomics: the promise of personalized medicine for CNS disorders.

  2009cited by this paper
• Common variants conferring risk of schizophrenia

  2009cited by this paper
• Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.

  2009cited by this paper
• Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

  2009cited by this paper
• The Effects of Transdermal Nicotine on Cognition in Nonsmokers with Schizophrenia and Nonpsychiatric Controls

  2008cited by this paper
• Bioinformatics challenges of new sequencing technology.

  2008cited by this paper
• Adjunctive galantamine, but not donepezil, enhances the antipsychotic-like effect of raclopride in rats.

  2008cited by this paper
• Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism.

  2008cited by this paper
• What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It?

  2008cited by this paper
• Amyloid imaging in Alzheimer's disease.

  2008cited by this paper
• Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.

  2008cited by this paper
• The FDA critical path initiative and its influence on new drug development.

  2008cited by this paper
• Outcomes in major depressive disorder: The evolving concept of remission and its implications for treatment

  2008cited by this paper
• Large recurrent microdeletions associated with schizophrenia

  2008cited by this paper
• How has DISC1 enabled drug discovery?

  2008cited by this paper
• Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia

  2008cited by this paper
• Genomewide Association for Major Depressive Disorder: A possible role for the presynaptic protein Piccolo

  2008cited by this paper
• Developing translational animal models for symptoms of schizophrenia or bipolar mania

  2008cited by this paper
• Off-label prescription of quetiapine in psychiatric disorders

  2007cited by this paper
• Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database

  2007cited by this paper
• Towards a muscarinic hypothesis of schizophrenia

  2007cited by this paper
• Amyloid imaging in Alzheimer's disease

  2007cited by this paper
• Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia.

  2007cited by this paper
• Polypharmacy in schizophrenia

  2006cited by this paper
• Media Portrayal of Mental Illness and its Treatments

  2006cited by this paper
• Neural systems involved in fear and anxiety measured with fear-potentiated startle.

  2006cited by this paper
• Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application.

  2006cited by this paper
• Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology.

  2006cited by this paper
• AmpliChip CYP450 Test: personalized medicine has arrived in psychiatry

  2006cited by this paper
• No change in cortical muscarinic M2, M3 receptors or [35S]GTPgammaS binding in schizophrenia.

  2006cited by this paper
• The family of sensorimotor gating disorders: Comorbidities or diagnostic overlaps?

  2006cited by this paper
• AmpliChip CYP450 test: personalized medicine has arrived in psychiatry.

  2006cited by this paper
• Interrogating the druggable genome with structural informatics

  2006cited by this paper
• How Stress and Fluoxetine Modulate Serotonin 2C Receptor Pre-mRNA Editing

  2005cited by this paper
• Placebo Effects Mediated by Endogenous Opioid Activity on μ-Opioid Receptors

  2005cited by this paper
• Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia.

  2005cited by this paper
• A pathophysiological paradigm for the therapy of psychiatric disease

  2005cited by this paper
• History of the discovery and clinical introduction of chlorpromazine.

  2005cited by this paper
• Antipsychotic agents. Gradually improving treatment from the traditional oral neuroleptics to the first atypical depot

  2005cited by this paper
• M1 Receptor Agonism, a Possible Treatment for Cognitive Deficits in Schizophrenia

  2004cited by this paper
• Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear.

  2004cited by this paper
• Managing psychotropic drug costs: will formularies work?

  2003cited by this paper
• Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.

  2003cited by this paper
• The Muscarinic M1/M4 Receptor Agonist Xanomeline Exhibits Antipsychotic-Like Activity in Cebus apella Monkeys

  2003cited by this paper
• Does publicizing hospital performance stimulate quality improvement efforts?

  2003cited by this paper
• In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia.

  2003cited by this paper
• Quantifying fear potentiated startle using absolute versus proportional increase scoring methods: implications for the neurocircuitry of fear and anxiety

  2002cited by this paper
• Prefrontal Dopamine D1 Receptors and Working Memory in Schizophrenia

  2002cited by this paper
• Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia

  2002cited by this paper
• Neuregulin 1 and susceptibility to schizophrenia.

  2002cited by this paper
• Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims.

  2002cited by this paper
• Changes in the Molecular Structure of the Brain in Bipolar Disorder: Findings using Human Postmortem Brain Tissue

  2002cited by this paper
• Developing novel treatments for mood disorders: accelerating discovery.

  2002cited by this paper

• Drug development in psychiatry: 50 years of failure and how to resuscitate it.

  2025cites this paper
• Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal

  2023cites this paper
• RETRACTED ARTICLE: Molecular communication networks: drug target scalability based on artificial intelligence prediction techniques

  2021cites this paper
• Clinical Research Center for Neuromodulation in Psychiatry: A Multi-Center Initiative to Advance Interventional Psychiatry in India

  2021cites this paper
• The benefits of in silico modeling to identify possible small-molecule drugs and their off-target interactions.

  2018influential citation
• Improved Scalability of Neuron-Based Phenotypic Screening Assays for Therapeutic Discovery in Neuropsychiatric Disorders

  2017cites this paper
• Some leopards can change their spots: potential repositioning of stem cell reprogramming compounds as anti-cancer agents

  2016cites this paper
• Allosteric modulation of cholinergic system: Potential approach to treating cognitive deficits of schizophrenia

  2016cites this paper
• Development and characterisation of a novel preclinical test battery for detecting anxiolytic and antidepressant properties of drugs

  2016cites this paper
• Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders.

  2015cites this paper
• Possible involvement of muscarinic receptors in psychiatric disorders: a focus on schizophrenia and mood disorders.

  2015cites this paper
• Proceedings of the 2013 CINP Summit: Innovative Partnerships to Accelerate CNS Drug Discovery for Improved Patient Care

  2015cites this paper
• The bipolar maze: a roadmap through translational psychopathology

  2014cites this paper